FTC: Nothing Improper Done in Investigation of Watson

The FTC says it did not engage in improper behavior as part of its pay-for-delay investigation into Watson Pharmaceuticals and has reaffirmed its request to subpoena CEO Paul Bisaro to see if the company brokered an illicit deal to keep Provigil generics off the market. The commission also rebuts an accusation from Bisaro that it attempted to forge a deal between Watson and Apotex to produce a generic version of Provigil (modafinil), according to an FTC filing.
Washington Drug Letter